Core Viewpoint - The article highlights the recent ESG (Environmental, Social, and Governance) risks associated with A-share listed companies, particularly focusing on incidents involving Jin Cheng Pharmaceutical and Fu Pai Ejiao, which reflect significant governance issues and compliance shortcomings in the pharmaceutical industry [1][9]. Group 1: ESG Risk Monitoring - A total of 837 A-share listed companies were reported by central and provincial media for sensitive information from October 6 to October 12, with a decrease of 1,082 companies compared to the previous week and an increase of 505 companies [1]. - The ESG sensitive information primarily pertains to governance and compliance, equity and asset issues, and risk management [1]. Group 2: Jin Cheng Pharmaceutical - Jin Cheng Pharmaceutical's actual controller, Zhao Yeqing, is facing a proposed fine of 1.5 million yuan for market manipulation, with total fines for involved parties amounting to 3 million yuan [2]. - The investigation into Jin Cheng Pharmaceutical has lasted over a year, with Zhao Yeqing receiving a market ban for four years, while other involved parties face shorter bans [2][4]. - Financially, Jin Cheng Pharmaceutical reported a revenue of 1.36 billion yuan for the first half of 2025, a decrease of 22.65% year-on-year, and a net profit of 43.38 million yuan, down 66.78% year-on-year [8]. Group 3: Fu Pai Ejiao - Fu Pai Ejiao and its subsidiary have been listed as defendants in multiple court cases, with execution amounts of 25,020 yuan and 67,300 yuan respectively [10][11]. - The company has faced challenges in its attempts to go public, having previously terminated listing preparations and withdrawn from advisory processes [12]. - Fu Pai Ejiao is also seeking international expansion, having established a joint venture in Macau, although the impact on its operational status remains uncertain [13].